Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe

Na<sub>V</sub>1.3 is a subtype of the voltage-gated sodium channel family. It has been implicated in the pathogenesis of neuropathic pain, although the contribution of this channel to neuronal excitability is not well understood. Tf2, a β-scorpion toxin previously identified from the ven...

Full description

Bibliographic Details
Main Authors: Mathilde R. Israel, Thomas S. Dash, Stefanie N. Bothe, Samuel D. Robinson, Jennifer R. Deuis, David J. Craik, Angelika Lampert, Irina Vetter, Thomas Durek
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Biomedicines
Subjects:
Tf2
Online Access:https://www.mdpi.com/2227-9059/8/6/155
id doaj-6b1890e16f0b48d49c998f2612d6eab5
record_format Article
spelling doaj-6b1890e16f0b48d49c998f2612d6eab52020-11-25T02:48:27ZengMDPI AGBiomedicines2227-90592020-06-01815515510.3390/biomedicines8060155Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological ProbeMathilde R. Israel0Thomas S. Dash1Stefanie N. Bothe2Samuel D. Robinson3Jennifer R. Deuis4David J. Craik5Angelika Lampert6Irina Vetter7Thomas Durek8Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute of Physiology, Medical Faculty, RWTH Aachen University, 52074 Aachen, GermanyInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute of Physiology, Medical Faculty, RWTH Aachen University, 52074 Aachen, GermanyInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, AustraliaNa<sub>V</sub>1.3 is a subtype of the voltage-gated sodium channel family. It has been implicated in the pathogenesis of neuropathic pain, although the contribution of this channel to neuronal excitability is not well understood. Tf2, a β-scorpion toxin previously identified from the venom of <i>Tityus fasciolatus</i>, has been reported to selectively activate Na<sub>V</sub>1.3. Here, we describe the activity of synthetic Tf2 and assess its suitability as a pharmacological probe for Na<sub>V</sub>1.3. As described for the native toxin, synthetic Tf2 (1 µM) caused early channel opening, decreased the peak current, and shifted the voltage dependence of Na<sub>V</sub>1.3 activation in the hyperpolarizing direction by −11.3 mV, with no activity at Na<sub>V</sub>1.1, Na<sub>V</sub>1.2, and Na<sub>V</sub>1.4-Na<sub>V</sub>1.8. Additional activity was found at Na<sub>V</sub>1.9, tested using the hNav1.9_C4 chimera, where Tf2 (1 µM) shifted the voltage dependence of activation by −6.3 mV. In an attempt to convert Tf2 into an Na<sub>V</sub>1.3 inhibitor, we synthetized the analogue Tf2[S14R], a mutation previously described to remove the excitatory activity of related β-scorpion toxins. Indeed, Tf2[S14R](10 µM) had reduced excitatory activity at Na<sub>V</sub>1.3, although it still caused a small −5.8 mV shift in the voltage dependence of activation. Intraplantar injection of Tf2 (1 µM) in mice caused spontaneous flinching and swelling, which was not reduced by the Na<sub>V</sub>1.1/1.3 inhibitor ICA-121431 nor in Na<sub>V</sub>1.9<sup>-/-</sup> mice, suggesting off-target activity. In addition, despite a loss of excitatory activity, intraplantar injection of Tf2[S14R](10 µM) still caused swelling, providing strong evidence that Tf2 has additional off-target activity at one or more non-neuronal targets. Therefore, due to activity at Na<sub>V</sub>1.9 and other yet to be identified target(s), the use of Tf2 as a selective pharmacological probe may be limited.https://www.mdpi.com/2227-9059/8/6/155Tf2sodium channelNa<sub>V</sub>1.3Na<sub>V</sub>1.9scorpiontoxin
collection DOAJ
language English
format Article
sources DOAJ
author Mathilde R. Israel
Thomas S. Dash
Stefanie N. Bothe
Samuel D. Robinson
Jennifer R. Deuis
David J. Craik
Angelika Lampert
Irina Vetter
Thomas Durek
spellingShingle Mathilde R. Israel
Thomas S. Dash
Stefanie N. Bothe
Samuel D. Robinson
Jennifer R. Deuis
David J. Craik
Angelika Lampert
Irina Vetter
Thomas Durek
Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
Biomedicines
Tf2
sodium channel
Na<sub>V</sub>1.3
Na<sub>V</sub>1.9
scorpion
toxin
author_facet Mathilde R. Israel
Thomas S. Dash
Stefanie N. Bothe
Samuel D. Robinson
Jennifer R. Deuis
David J. Craik
Angelika Lampert
Irina Vetter
Thomas Durek
author_sort Mathilde R. Israel
title Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
title_short Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
title_full Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
title_fullStr Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
title_full_unstemmed Characterization of Synthetic Tf2 as a Na<sub>V</sub>1.3 Selective Pharmacological Probe
title_sort characterization of synthetic tf2 as a na<sub>v</sub>1.3 selective pharmacological probe
publisher MDPI AG
series Biomedicines
issn 2227-9059
publishDate 2020-06-01
description Na<sub>V</sub>1.3 is a subtype of the voltage-gated sodium channel family. It has been implicated in the pathogenesis of neuropathic pain, although the contribution of this channel to neuronal excitability is not well understood. Tf2, a β-scorpion toxin previously identified from the venom of <i>Tityus fasciolatus</i>, has been reported to selectively activate Na<sub>V</sub>1.3. Here, we describe the activity of synthetic Tf2 and assess its suitability as a pharmacological probe for Na<sub>V</sub>1.3. As described for the native toxin, synthetic Tf2 (1 µM) caused early channel opening, decreased the peak current, and shifted the voltage dependence of Na<sub>V</sub>1.3 activation in the hyperpolarizing direction by −11.3 mV, with no activity at Na<sub>V</sub>1.1, Na<sub>V</sub>1.2, and Na<sub>V</sub>1.4-Na<sub>V</sub>1.8. Additional activity was found at Na<sub>V</sub>1.9, tested using the hNav1.9_C4 chimera, where Tf2 (1 µM) shifted the voltage dependence of activation by −6.3 mV. In an attempt to convert Tf2 into an Na<sub>V</sub>1.3 inhibitor, we synthetized the analogue Tf2[S14R], a mutation previously described to remove the excitatory activity of related β-scorpion toxins. Indeed, Tf2[S14R](10 µM) had reduced excitatory activity at Na<sub>V</sub>1.3, although it still caused a small −5.8 mV shift in the voltage dependence of activation. Intraplantar injection of Tf2 (1 µM) in mice caused spontaneous flinching and swelling, which was not reduced by the Na<sub>V</sub>1.1/1.3 inhibitor ICA-121431 nor in Na<sub>V</sub>1.9<sup>-/-</sup> mice, suggesting off-target activity. In addition, despite a loss of excitatory activity, intraplantar injection of Tf2[S14R](10 µM) still caused swelling, providing strong evidence that Tf2 has additional off-target activity at one or more non-neuronal targets. Therefore, due to activity at Na<sub>V</sub>1.9 and other yet to be identified target(s), the use of Tf2 as a selective pharmacological probe may be limited.
topic Tf2
sodium channel
Na<sub>V</sub>1.3
Na<sub>V</sub>1.9
scorpion
toxin
url https://www.mdpi.com/2227-9059/8/6/155
work_keys_str_mv AT mathilderisrael characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT thomassdash characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT stefanienbothe characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT samueldrobinson characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT jenniferrdeuis characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT davidjcraik characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT angelikalampert characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT irinavetter characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
AT thomasdurek characterizationofsynthetictf2asanasubvsub13selectivepharmacologicalprobe
_version_ 1724747746338930688